It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such as, Staphylococcus aureus, rather than from the lymphoma per se. Here, we examined if staphylococcal enterotoxins (SE) may shape the phenotype of malignant SS cells, including expression of the regulatory T-cell-associated marker FOXP3. Our studies with primary and cultured malignant cells show that SE induce expression of FOXP3 in malignant cells when exposed to nonmalignant cells. Mutations in the MHC class II binding domain of SE-A (SEA) largely block the effect indicating that the response relies at least in part on the MHC class II-mediated antigen presentation. Transwell experiments show that the effect is induced by soluble factors, partly blocked by anti-IL-2 antibody, and depends on STAT5 activation in malignant cells. Collectively, these findings show that SE stimulate nonmalignant cells to induce FOXP3 expression in malignant cells. Thus, differences in exposure to environmental factors, such as bacterial toxins may explain the heterogeneous FOXP3 expression in malignant cells in SS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Copenhagen, Department of Immunology and Microbiology; LEO Foundation Skin Immunology Research Center, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
2 Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark (GRID:grid.154185.c) (ISNI:0000 0004 0512 597X)
3 Leiden University Medical Center, Department of Dermatology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
4 University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
5 German Cancer Consortium (DKTK), University Hospital of Essen, Department of Translational Skin Cancer Research, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); Deutsches Krebsforschungsinstitut (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
6 Herlev Hospital, University of Copenhagen, Center for Cancer Immune Therapy, Department of Hematology, Herlev, Denmark (GRID:grid.411900.d) (ISNI:0000 0004 0646 8325)
7 Zealand University Hospital, Department of Pathology, Roskilde, Denmark (GRID:grid.476266.7)
8 McGill University Health Centre, Division of Dermatology, Montreal, Canada (GRID:grid.63984.30) (ISNI:0000 0000 9064 4811)